{"id":41958,"date":"2025-09-22T14:47:38","date_gmt":"2025-09-22T06:47:38","guid":{"rendered":"https:\/\/flcube.com\/?p=41958"},"modified":"2025-09-22T14:47:38","modified_gmt":"2025-09-22T06:47:38","slug":"ausperbio-secures-63-million-series-b2-financing-to-propel-ahb%e2%80%91137-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41958","title":{"rendered":"AusperBio Secures $63\u202fMillion Series\u202fB2 Financing to Propel AHB\u2011137 Development"},"content":{"rendered":"\n

AusperBio Therapeutics, Inc.<\/strong> and Ausper Biopharma Co., Ltd.<\/strong> (collectively \u201cAusperBio\u201d) announced that it has closed a USD\u202f63\u202fmillion Series\u202fB2 financing round<\/strong>. The round was co\u2011led by Qiming Venture Partners<\/strong> and a globally\u2011renowned industrial\u2011investment firm, with participation from top domestic investors such as Hankang Capital, CDH VGC, Yuanbio Ventures, Sherpa Healthcare Partners, and Genesis Capital<\/strong>. This marks AusperBio\u2019s second successful raise in 2025, bringing the company\u2019s total capital inflow for the year to over USD\u202f113\u202fmillion<\/strong>.<\/p>\n\n\n\n

Funding Highlights<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Series\u202fB2 Amount<\/strong><\/td>USD\u202f63\u202fmillion<\/td><\/tr>
Co\u2011Leads<\/strong><\/td>Qiming Venture Partners; unnamed industrial investment firm<\/td><\/tr>
Other Investors<\/strong><\/td>Hankang Capital, CDH VGC, Yuanbio Ventures, Sherpa Healthcare Partners, Genesis Capital<\/td><\/tr>
Total 2025 Funding<\/strong><\/td>> USD\u202f113\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Uses of Capital<\/h2>\n\n\n\n
    \n
  1. Accelerate Clinical Development of AHB\u2011137<\/strong> \u2013 The lead small\u2011molecule candidate targeting the Hsp90\u2011Cdc37 complex is slated for a pivotal Phase\u202fII trial in early\u2011stage solid tumours.<\/li>\n\n\n\n
  2. Support Future Commercialization & Industrialization<\/strong> \u2013 Funding will underpin pre\u2011commercial manufacturing scale\u2011up, regulatory filing preparations, and early\u2011stage market access strategies.<\/li>\n\n\n\n
  3. Expand Innovation Pipeline<\/strong> \u2013 Capital will back the discovery of next\u2011generation protein\u2011degradation and targeted\u2011oncology assets.<\/li>\n\n\n\n
  4. Strengthen Global Talent Pool<\/strong> \u2013 AusperBio plans to recruit senior scientists, clinical experts, and regulatory specialists in China and the U.S.<\/li>\n<\/ol>\n\n\n\n

    Market Perspective<\/h2>\n\n\n\n